Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 11, 2025 Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were $-0.35. Operator: Good afternoon, and welcome to Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call.
Voyager Therapeutics: Q4 Earnings Snapshot
The gene therapy company posted revenue of $6.3 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $20.1 million. For the year, the company reported a loss of $65 million, or $1.13 per share. Revenue was reported as $80 million.
Dorel Industries: Q4 Earnings Snapshot
Dorel Industries Inc. (DIIBF) on Tuesday reported a loss of $73 million in its fourth quarter. On a per-share basis, the Westmount, Quebec-based company said it had a loss of $2.24. Losses, adjusted for one-time gains and costs,
Phreesia: Fiscal Q4 Earnings Snapshot
(PHR) on Wednesday reported a loss of $6.4 million in its fiscal fourth quarter. The Wilmington, Delaware-based company said it had a loss of 11 cents per share. The results exceeded Wall Street expectations.
AudioEye: Q4 Earnings Snapshot
AudioEye, Inc. (AEYE) on Wednesday
Performant Healthcare: Q4 Earnings Snapshot
Performant Healthcare expects full-year revenue in the range of $131 million to $135 million. This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zack
Upland Software: Q4 Earnings Snapshot
For the current quarter ending in March, Upland Software said it expects revenue in the range of $59 million to $65 million. The company expects full-year revenue in the range of $231.5 million to $255.
Phoenix New Media: Q4 Earnings Snapshot
Phoenix New Media Ltd. (FENG) on Tuesday reported a loss of $493,000 in its fourth quarter. The Beijing-based company said it had a loss of 4 cents per share. Earnings, adjusted for non-recurring costs and stock option expense,
Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Voyager Therapeutics (VYGR) to $10 from $12 and keeps an Overweight rating on ...
Zacks.com on MSN23h
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...
Wells Fargo Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...
Nasdaq2d
VOYAGER THERAPEUTICS Earnings Preview: Recent $VYGR Insider Trading, Hedge Fund Activity, and More
VOYAGER THERAPEUTICS ($VYGR) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting revenue ...
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $15.72 Average Price Target from Analysts
Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ...
Voyager reports promising data for early stage trial in Alzheimer’s disease treatment
Voyager Therapeutics (VYGR) said on Monday that the company provided positive topline data from its early stage trial of VY7523, an antibody to selectively inhibit the spread of pathological tau in ...
Morningstar23d
Voyager Therapeutics Inc VYGR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a report released on ...
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), Senseonics Holdings (SENS) and Voyager Therapeutics (VYGR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Elanco Animal Health (ELAN – Research ...